Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.35 |
| ▸ | RARB | P10826 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25223336 | 0.90 | PSMD10 (0.39) | DGAT1KMT2ANPC1KDM4EALDH1A1 | |
| SCHEMBL25215381 | 0.88 | DGAT1 (0.34) | KLKB1DGAT1MEN1KMT2ANPC1 | |
| SCHEMBL25258342 | 0.83 | DGAT1 (0.37) | KLKB1DGAT1RARBMEN1KMT2A | |
| SCHEMBL25213344 | 0.80 | TBXAS1 (0.34) | RARBMEN1KMT2ANPC1 | |
| SCHEMBL25268981 | 0.79 | DGAT1 (0.34) | KLKB1DGAT1RARBMEN1KMT2A | |
| SCHEMBL25242686 | 0.79 | CA12 (0.36) | DGAT1NPC1KDM4EALDH1A1 | |
| SCHEMBL25215427 | 0.78 | MEN1 (0.33) | KLKB1DGAT1MEN1KMT2ANPC1 | |
| SCHEMBL25214568 | 0.78 | DGAT1 (0.36) | KLKB1DGAT1RARBMEN1KMT2A | |
| SCHEMBL25254364 | 0.77 | NPC1 (0.36) | DGAT1RARBMEN1KMT2ARARA | |
| SCHEMBL25211606 | 0.75 | NPC1 (0.36) | DGAT1RARBMEN1KMT2ARARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4441033-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2023102162-A1 | TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | KLKB1 2165/4885DGAT1 1440/4885RARB 653/4885 |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | KLKB1 2006/4885DGAT1 1931/4885RARB 807/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | KLKB1 2006/4885DGAT1 1931/4885RARB 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.